Overview and Approach to Medical Management of Male Pattern Hair Loss

2016 ◽  
pp. 79-79
Author(s):  
Samipa Mukherjee ◽  
Madura C ◽  
Chandrashekar BS
2007 ◽  
Vol 8 (5) ◽  
pp. 285-290 ◽  
Author(s):  
Hyo Seung Shin ◽  
Chong Hyun Won ◽  
Seung Ho Lee ◽  
Oh Sang Kwon ◽  
Kyu Han Kim ◽  
...  
Keyword(s):  

2020 ◽  
Vol 19 (7) ◽  
pp. 1545-1547 ◽  
Author(s):  
Andy Goren ◽  
Sergio Vaño‐Galván ◽  
Carlos Gustavo Wambier ◽  
John McCoy ◽  
Alba Gomez‐Zubiaur ◽  
...  

2002 ◽  
Vol 90 (7) ◽  
pp. 682-685 ◽  
Author(s):  
W.R. Anderson ◽  
N.M. Harris ◽  
S.A.V. Holmes

2006 ◽  
Vol 59 (11) ◽  
pp. 1162-1169 ◽  
Author(s):  
Nesrin Tan Baser ◽  
Bulent Cigsar ◽  
Unzile Balci Akbuga ◽  
Ahmet Terzioglu ◽  
Gurcan Aslan

2014 ◽  
Vol 9 (3) ◽  
pp. 222-228 ◽  
Author(s):  
Christine Anne Ganzer ◽  
Alan Roy Jacobs ◽  
Farin Iqbal

Finasteride is a synthetic 5-α reductase inhibitor, which prevents the conversion of testosterone to dihydrotestosterone and has been used for more than 20 years in the treatment of male pattern hair loss. Randomized, controlled trials have associated finasteride with both reversible and persistent adverse effects. In this pilot study, we sought to characterize sexual and nonsexual adverse effects that men reported experiencing at least 3 months after stopping the medication. Based on previous research on persistent side effects of finasteride, we constructed an Internet survey targeting six domains: physical symptoms, sexual libido, ejaculatory disorders, disorders of the penis and testes, cognitive symptoms, and psychological symptoms and was e-mailed to patients who reported experiencing symptoms of side effects of finasteride. Responses from 131 generally healthy men (mean age, 24 years) who had taken finasteride for male pattern hair loss was included in the analysis. The most notable finding was that adverse effects persisted in each of the domains, indicating the possible presence of a “post-finasteride syndrome.”


Sign in / Sign up

Export Citation Format

Share Document